scholarly journals PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA

2010 ◽  
Vol 13 (7) ◽  
pp. A514 ◽  
Author(s):  
YG Kim ◽  
EK Lee
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Effectiveness Analysis ◽  
Third Line ◽  
Third Line Treatment

scholarly journals Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

2021 ◽  
pp. 1-1
Author(s):  
Caitlin Smare ◽  
Kiran Dave ◽  
Ariadna Juarez-Garcia ◽  
Pranav Abraham ◽  
John R. Penrod ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

Second and third line treatment in non-small cell lung cancer

2009 ◽  
Vol 71 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Adolfo Favaretto ◽  
Giulia Pasello ◽  
Cristina Magro ◽  
Clorinda Schettino ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment
Sign in / Sign up

Export Citation Format

Share Document